Neuroendocrine Carcinoma Market
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neuroendocrine Carcinoma Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Chemotherapy
1.2.3 Somatostatin Analogs
1.2.4 Targeted Therapy
1.3 Market by Application
1.3.1 Global Neuroendocrine Carcinoma Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Oncology Centres
1.3.5 Ambulatory Surgery Centres
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Neuroendocrine Carcinoma Market Perspective (2017-2028)
2.2 Neuroendocrine Carcinoma Growth Trends by Region
2.2.1 Neuroendocrine Carcinoma Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Neuroendocrine Carcinoma Historic Market Size by Region (2017-2022)
2.2.3 Neuroendocrine Carcinoma Forecasted Market Size by Region (2023-2028)
2.3 Neuroendocrine Carcinoma Market Dynamics
2.3.1 Neuroendocrine Carcinoma Industry Trends
2.3.2 Neuroendocrine Carcinoma Market Drivers
2.3.3 Neuroendocrine Carcinoma Market Challenges
2.3.4 Neuroendocrine Carcinoma Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neuroendocrine Carcinoma Players by Revenue
3.1.1 Global Top Neuroendocrine Carcinoma Players by Revenue (2017-2022)
3.1.2 Global Neuroendocrine Carcinoma Revenue Market Share by Players (2017-2022)
3.2 Global Neuroendocrine Carcinoma Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Neuroendocrine Carcinoma Revenue
3.4 Global Neuroendocrine Carcinoma Market Concentration Ratio
3.4.1 Global Neuroendocrine Carcinoma Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neuroendocrine Carcinoma Revenue in 2021
3.5 Neuroendocrine Carcinoma Key Players Head office and Area Served
3.6 Key Players Neuroendocrine Carcinoma Product Solution and Service
3.7 Date of Enter into Neuroendocrine Carcinoma Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neuroendocrine Carcinoma Breakdown Data by Type
4.1 Global Neuroendocrine Carcinoma Historic Market Size by Type (2017-2022)
4.2 Global Neuroendocrine Carcinoma Forecasted Market Size by Type (2023-2028)
5 Neuroendocrine Carcinoma Breakdown Data by Application
5.1 Global Neuroendocrine Carcinoma Historic Market Size by Application (2017-2022)
5.2 Global Neuroendocrine Carcinoma Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Neuroendocrine Carcinoma Market Size (2017-2028)
6.2 North America Neuroendocrine Carcinoma Market Size by Country (2017-2022)
6.3 North America Neuroendocrine Carcinoma Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Neuroendocrine Carcinoma Market Size (2017-2028)
7.2 Europe Neuroendocrine Carcinoma Market Size by Country (2017-2022)
7.3 Europe Neuroendocrine Carcinoma Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neuroendocrine Carcinoma Market Size (2017-2028)
8.2 Asia-Pacific Neuroendocrine Carcinoma Market Size by Country (2017-2022)
8.3 Asia-Pacific Neuroendocrine Carcinoma Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Neuroendocrine Carcinoma Market Size (2017-2028)
9.2 Latin America Neuroendocrine Carcinoma Market Size by Country (2017-2022)
9.3 Latin America Neuroendocrine Carcinoma Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neuroendocrine Carcinoma Market Size (2017-2028)
10.2 Middle East & Africa Neuroendocrine Carcinoma Market Size by Country (2017-2022)
10.3 Middle East & Africa Neuroendocrine Carcinoma Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Neuroendocrine Carcinoma Introduction
11.1.4 Pfizer Revenue in Neuroendocrine Carcinoma Business (2017-2022)
11.1.5 Pfizer Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Neuroendocrine Carcinoma Introduction
11.2.4 Novartis Revenue in Neuroendocrine Carcinoma Business (2017-2022)
11.2.5 Novartis Recent Development
11.3 Chiasma
11.3.1 Chiasma Company Detail
11.3.2 Chiasma Business Overview
11.3.3 Chiasma Neuroendocrine Carcinoma Introduction
11.3.4 Chiasma Revenue in Neuroendocrine Carcinoma Business (2017-2022)
11.3.5 Chiasma Recent Development
11.4 Ipsen
11.4.1 Ipsen Company Detail
11.4.2 Ipsen Business Overview
11.4.3 Ipsen Neuroendocrine Carcinoma Introduction
11.4.4 Ipsen Revenue in Neuroendocrine Carcinoma Business (2017-2022)
11.4.5 Ipsen Recent Development
11.5 Abbvie
11.5.1 Abbvie Company Detail
11.5.2 Abbvie Business Overview
11.5.3 Abbvie Neuroendocrine Carcinoma Introduction
11.5.4 Abbvie Revenue in Neuroendocrine Carcinoma Business (2017-2022)
11.5.5 Abbvie Recent Development
11.6 Valeant
11.6.1 Valeant Company Detail
11.6.2 Valeant Business Overview
11.6.3 Valeant Neuroendocrine Carcinoma Introduction
11.6.4 Valeant Revenue in Neuroendocrine Carcinoma Business (2017-2022)
11.6.5 Valeant Recent Development
11.7 Jubilant
11.7.1 Jubilant Company Detail
11.7.2 Jubilant Business Overview
11.7.3 Jubilant Neuroendocrine Carcinoma Introduction
11.7.4 Jubilant Revenue in Neuroendocrine Carcinoma Business (2017-2022)
11.7.5 Jubilant Recent Development
11.8 Teva
11.8.1 Teva Company Detail
11.8.2 Teva Business Overview
11.8.3 Teva Neuroendocrine Carcinoma Introduction
11.8.4 Teva Revenue in Neuroendocrine Carcinoma Business (2017-2022)
11.8.5 Teva Recent Development
11.9 F.Hoffmann-La Roche
11.9.1 F.Hoffmann-La Roche Company Detail
11.9.2 F.Hoffmann-La Roche Business Overview
11.9.3 F.Hoffmann-La Roche Neuroendocrine Carcinoma Introduction
11.9.4 F.Hoffmann-La Roche Revenue in Neuroendocrine Carcinoma Business (2017-2022)
11.9.5 F.Hoffmann-La Roche Recent Development
11.10 Advanced Accelerator
11.10.1 Advanced Accelerator Company Detail
11.10.2 Advanced Accelerator Business Overview
11.10.3 Advanced Accelerator Neuroendocrine Carcinoma Introduction
11.10.4 Advanced Accelerator Revenue in Neuroendocrine Carcinoma Business (2017-2022)
11.10.5 Advanced Accelerator Recent Development
11.11 Mateon
11.11.1 Mateon Company Detail
11.11.2 Mateon Business Overview
11.11.3 Mateon Neuroendocrine Carcinoma Introduction
11.11.4 Mateon Revenue in Neuroendocrine Carcinoma Business (2017-2022)
11.11.5 Mateon Recent Development
11.12 Lexicon
11.12.1 Lexicon Company Detail
11.12.2 Lexicon Business Overview
11.12.3 Lexicon Neuroendocrine Carcinoma Introduction
11.12.4 Lexicon Revenue in Neuroendocrine Carcinoma Business (2017-2022)
11.12.5 Lexicon Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Neuroendocrine Carcinoma Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Key Players of Chemotherapy
Table 3. Key Players of Somatostatin Analogs
Table 4. Key Players of Targeted Therapy
Table 5. Global Neuroendocrine Carcinoma Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 6. Global Neuroendocrine Carcinoma Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 7. Global Neuroendocrine Carcinoma Market Size by Region (2017-2022) & (US$ Million)
Table 8. Global Neuroendocrine Carcinoma Market Share by Region (2017-2022)
Table 9. Global Neuroendocrine Carcinoma Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 10. Global Neuroendocrine Carcinoma Market Share by Region (2023-2028)
Table 11. Neuroendocrine Carcinoma Market Trends
Table 12. Neuroendocrine Carcinoma Market Drivers
Table 13. Neuroendocrine Carcinoma Market Challenges
Table 14. Neuroendocrine Carcinoma Market Restraints
Table 15. Global Neuroendocrine Carcinoma Revenue by Players (2017-2022) & (US$ Million)
Table 16. Global Neuroendocrine Carcinoma Market Share by Players (2017-2022)
Table 17. Global Top Neuroendocrine Carcinoma Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuroendocrine Carcinoma as of 2021)
Table 18. Ranking of Global Top Neuroendocrine Carcinoma Companies by Revenue (US$ Million) in 2021
Table 19. Global 5 Largest Players Market Share by Neuroendocrine Carcinoma Revenue (CR5 and HHI) & (2017-2022)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Neuroendocrine Carcinoma Product Solution and Service
Table 22. Date of Enter into Neuroendocrine Carcinoma Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Neuroendocrine Carcinoma Market Size by Type (2017-2022) & (US$ Million)
Table 25. Global Neuroendocrine Carcinoma Revenue Market Share by Type (2017-2022)
Table 26. Global Neuroendocrine Carcinoma Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 27. Global Neuroendocrine Carcinoma Revenue Market Share by Type (2023-2028)
Table 28. Global Neuroendocrine Carcinoma Market Size by Application (2017-2022) & (US$ Million)
Table 29. Global Neuroendocrine Carcinoma Revenue Market Share by Application (2017-2022)
Table 30. Global Neuroendocrine Carcinoma Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 31. Global Neuroendocrine Carcinoma Revenue Market Share by Application (2023-2028)
Table 32. North America Neuroendocrine Carcinoma Market Size by Country (2017-2022) & (US$ Million)
Table 33. North America Neuroendocrine Carcinoma Market Size by Country (2023-2028) & (US$ Million)
Table 34. Europe Neuroendocrine Carcinoma Market Size by Country (2017-2022) & (US$ Million)
Table 35. Europe Neuroendocrine Carcinoma Market Size by Country (2023-2028) & (US$ Million)
Table 36. Asia-Pacific Neuroendocrine Carcinoma Market Size by Region (2017-2022) & (US$ Million)
Table 37. Asia-Pacific Neuroendocrine Carcinoma Market Size by Region (2023-2028) & (US$ Million)
Table 38. Latin America Neuroendocrine Carcinoma Market Size by Country (2017-2022) & (US$ Million)
Table 39. Latin America Neuroendocrine Carcinoma Market Size by Country (2023-2028) & (US$ Million)
Table 40. Middle East & Africa Neuroendocrine Carcinoma Market Size by Country (2017-2022) & (US$ Million)
Table 41. Middle East & Africa Neuroendocrine Carcinoma Market Size by Country (2023-2028) & (US$ Million)
Table 42. Pfizer Company Detail
Table 43. Pfizer Business Overview
Table 44. Pfizer Neuroendocrine Carcinoma Product
Table 45. Pfizer Revenue in Neuroendocrine Carcinoma Business (2017-2022) & (US$ Million)
Table 46. Pfizer Recent Development
Table 47. Novartis Company Detail
Table 48. Novartis Business Overview
Table 49. Novartis Neuroendocrine Carcinoma Product
Table 50. Novartis Revenue in Neuroendocrine Carcinoma Business (2017-2022) & (US$ Million)
Table 51. Novartis Recent Development
Table 52. Chiasma Company Detail
Table 53. Chiasma Business Overview
Table 54. Chiasma Neuroendocrine Carcinoma Product
Table 55. Chiasma Revenue in Neuroendocrine Carcinoma Business (2017-2022) & (US$ Million)
Table 56. Chiasma Recent Development
Table 57. Ipsen Company Detail
Table 58. Ipsen Business Overview
Table 59. Ipsen Neuroendocrine Carcinoma Product
Table 60. Ipsen Revenue in Neuroendocrine Carcinoma Business (2017-2022) & (US$ Million)
Table 61. Ipsen Recent Development
Table 62. Abbvie Company Detail
Table 63. Abbvie Business Overview
Table 64. Abbvie Neuroendocrine Carcinoma Product
Table 65. Abbvie Revenue in Neuroendocrine Carcinoma Business (2017-2022) & (US$ Million)
Table 66. Abbvie Recent Development
Table 67. Valeant Company Detail
Table 68. Valeant Business Overview
Table 69. Valeant Neuroendocrine Carcinoma Product
Table 70. Valeant Revenue in Neuroendocrine Carcinoma Business (2017-2022) & (US$ Million)
Table 71. Valeant Recent Development
Table 72. Jubilant Company Detail
Table 73. Jubilant Business Overview
Table 74. Jubilant Neuroendocrine Carcinoma Product
Table 75. Jubilant Revenue in Neuroendocrine Carcinoma Business (2017-2022) & (US$ Million)
Table 76. Jubilant Recent Development
Table 77. Teva Company Detail
Table 78. Teva Business Overview
Table 79. Teva Neuroendocrine Carcinoma Product
Table 80. Teva Revenue in Neuroendocrine Carcinoma Business (2017-2022) & (US$ Million)
Table 81. Teva Recent Development
Table 82. F.Hoffmann-La Roche Company Detail
Table 83. F.Hoffmann-La Roche Business Overview
Table 84. F.Hoffmann-La Roche Neuroendocrine Carcinoma Product
Table 85. F.Hoffmann-La Roche Revenue in Neuroendocrine Carcinoma Business (2017-2022) & (US$ Million)
Table 86. F.Hoffmann-La Roche Recent Development
Table 87. Advanced Accelerator Company Detail
Table 88. Advanced Accelerator Business Overview
Table 89. Advanced Accelerator Neuroendocrine Carcinoma Product
Table 90. Advanced Accelerator Revenue in Neuroendocrine Carcinoma Business (2017-2022) & (US$ Million)
Table 91. Advanced Accelerator Recent Development
Table 92. Mateon Company Detail
Table 93. Mateon Business Overview
Table 94. Mateon Neuroendocrine CarcinomaProduct
Table 95. Mateon Revenue in Neuroendocrine Carcinoma Business (2017-2022) & (US$ Million)
Table 96. Mateon Recent Development
Table 97. Lexicon Company Detail
Table 98. Lexicon Business Overview
Table 99. Lexicon Neuroendocrine CarcinomaProduct
Table 100. Lexicon Revenue in Neuroendocrine Carcinoma Business (2017-2022) & (US$ Million)
Table 101. Lexicon Recent Development
Table 102. Research Programs/Design for This Report
Table 103. Key Data Information from Secondary Sources
Table 104. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neuroendocrine Carcinoma Market Share by Type: 2021 VS 2028
Figure 2. Chemotherapy Features
Figure 3. Somatostatin Analogs Features
Figure 4. Targeted Therapy Features
Figure 5. Global Neuroendocrine Carcinoma Market Share by Application in 2021 & 2028
Figure 6. Hospital Case Studies
Figure 7. Clinics Case Studies
Figure 8. Oncology Centres Case Studies
Figure 9. Ambulatory Surgery Centres Case Studies
Figure 10. Neuroendocrine Carcinoma Report Years Considered
Figure 11. Global Neuroendocrine Carcinoma Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 12. Global Neuroendocrine Carcinoma Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 13. Global Neuroendocrine Carcinoma Market Share by Region: 2021 VS 2028
Figure 14. Global Neuroendocrine Carcinoma Market Share by Players in 2021
Figure 15. Global Top Neuroendocrine Carcinoma Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuroendocrine Carcinoma as of 2021)
Figure 16. The Top 10 and 5 Players Market Share by Neuroendocrine Carcinoma Revenue in 2021
Figure 17. North America Neuroendocrine Carcinoma Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 18. North America Neuroendocrine Carcinoma Market Share by Country (2017-2028)
Figure 19. United States Neuroendocrine Carcinoma Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 20. Canada Neuroendocrine Carcinoma Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 21. Europe Neuroendocrine Carcinoma Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 22. Europe Neuroendocrine Carcinoma Market Share by Country (2017-2028)
Figure 23. Germany Neuroendocrine Carcinoma Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. France Neuroendocrine Carcinoma Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 25. U.K. Neuroendocrine Carcinoma Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. Italy Neuroendocrine Carcinoma Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. Russia Neuroendocrine Carcinoma Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Nordic Countries Neuroendocrine Carcinoma Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Asia-Pacific Neuroendocrine Carcinoma Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Asia-Pacific Neuroendocrine Carcinoma Market Share by Region (2017-2028)
Figure 31. China Neuroendocrine Carcinoma Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Japan Neuroendocrine Carcinoma Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. South Korea Neuroendocrine Carcinoma Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. Southeast Asia Neuroendocrine Carcinoma Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. India Neuroendocrine Carcinoma Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Australia Neuroendocrine Carcinoma Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Latin America Neuroendocrine Carcinoma Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. Latin America Neuroendocrine Carcinoma Market Share by Country (2017-2028)
Figure 39. Mexico Neuroendocrine Carcinoma Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Brazil Neuroendocrine Carcinoma Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Middle East & Africa Neuroendocrine Carcinoma Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. Middle East & Africa Neuroendocrine Carcinoma Market Share by Country (2017-2028)
Figure 43. Turkey Neuroendocrine Carcinoma Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 44. Saudi Arabia Neuroendocrine Carcinoma Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 45. Pfizer Revenue Growth Rate in Neuroendocrine Carcinoma Business (2017-2022)
Figure 46. Novartis Revenue Growth Rate in Neuroendocrine Carcinoma Business (2017-2022)
Figure 47. Chiasma Revenue Growth Rate in Neuroendocrine Carcinoma Business (2017-2022)
Figure 48. Ipsen Revenue Growth Rate in Neuroendocrine Carcinoma Business (2017-2022)
Figure 49. Abbvie Revenue Growth Rate in Neuroendocrine Carcinoma Business (2017-2022)
Figure 50. Valeant Revenue Growth Rate in Neuroendocrine Carcinoma Business (2017-2022)
Figure 51. Jubilant Revenue Growth Rate in Neuroendocrine Carcinoma Business (2017-2022)
Figure 52. Teva Revenue Growth Rate in Neuroendocrine Carcinoma Business (2017-2022)
Figure 53. F.Hoffmann-La Roche Revenue Growth Rate in Neuroendocrine Carcinoma Business (2017-2022)
Figure 54. Advanced Accelerator Revenue Growth Rate in Neuroendocrine Carcinoma Business (2017-2022)
Figure 55. Mateon Revenue Growth Rate in Neuroendocrine Carcinoma Business (2017-2022)
Figure 56. Lexicon Revenue Growth Rate in Neuroendocrine Carcinoma Business (2017-2022)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
Industry Market Size
